文献速递临床试验与 GCP基础与转化研究

阿拉伯胶作为新诊断COVID-19患者免疫调节剂的随机对照试验方案结构化摘要

Potential Role of Acacia Senegal (Gum Arabic) as Immunomodulatory Agent among newly diagnosed COVID 19 Patients: A structured summary of a protocol for a randomised, controlled, clinical trial.
PubMed 文献 · Trials · 2020-09-05

该方案旨在研究口服阿拉伯胶(GA)作为免疫调节和抗炎膳食干预对新诊断苏丹COVID-19患者的潜在疗效。采用四盲、随机、安慰剂对照的II/III期优效性试验,计划纳入110例患者,主要结局为免疫应答评分变化及细胞因子水平变化。

要点

  • 四盲随机安慰剂对照设计,GA组每日30克口服,对照组每日1克果胶,疗程四周。
  • 主要结局包括免疫应答评分变化、TNFα、IL8、IL6、IL10及CRP水平变化和病毒载量。
  • 计划纳入110例新诊断COVID-19患者,年龄8-90岁,PCR确诊72小时内。

核心结论

  • 该方案旨在评估口服阿拉伯胶作为免疫调节和抗炎膳食干预对新诊断COVID-19患者的潜在疗效。

研究设计与样本

  • 四盲、随机、安慰剂对照的II/III期优效性试验,前瞻性、两臂、平行组设计,1:1分配比例。
  • 计划纳入110例符合条件的患者,随机分配至GA组(n=55)或安慰剂组(n=55)。
  • 研究对象为新诊断的COVID-19患者,经实时PCR确诊且在PCR后72小时内,年龄8-90岁,男女不限。
  • 排除标准包括:插管接受肠外治疗的患者、对阿拉伯胶过敏者。
  • 研究在苏丹喀土穆州的COVID隔离中心和Soba大学医院进行。

关键数值与推荐

  • 干预组:100%天然阿拉伯胶粉末,30克剂量每日一次,口服四周。
  • 对照组:果胶粉末,1克剂量每日一次,口服四周。
  • 两组均在接受基于当地临床指南的标准治疗基础上加用研究干预。
  • 主要结局:从基线至试验结束的免疫应答评分平均变化;TNFα、IL8、IL6、IL10水平相对基线的变化(随机化开始后四周);死亡率(随机化开始后四周内GA组与安慰剂组死亡百分比)。
  • 随机化采用计算机生成的随机数字序列,由独立人员执行,分配比例1:1,每个参与中心分配特殊代码。

临床怎么用

  • 若试验证实有效,阿拉伯胶可能作为新诊断COVID-19患者的辅助免疫调节膳食干预。
  • 干预需在标准治疗基础上加用,每日30克阿拉伯胶粉末口服,疗程四周。

局限性

  • 该文为试验方案结构化摘要,尚未报告实际研究结果。
  • 样本量计划为110例,试验预计完成日期为2021年1月15日,结果需待正式发表。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the potential efficacy of Acacia Senegal extract Gum Arabic (GA) supplementation as immunomodulatory and anti-inflammatory dietary intervention among newly diagnosed COVID 19 Sudanese patients. To study the effect of GA on the level of cytokines, TNFα, IL8, IL6 IL10, CRP and the viral load. Secondary outcomes will be the effect of GA oral intake on mortality rate and days of hospital admission. TRIAL DESIGN: Quadruple blind, randomized placebo-controlled clinical trial Phase II & III. Prospective, two-arm, parallel-group, randomised (1:1 allocation ratio) superiority trial of oral GA among seropositive COVID-19 patients. PARTICIPANTS: Inclusion criteria: COVID-19 infected (newly diagnosed) as proved by real-time PCR within 72 hours of PCR. Age 8-90 years Both genders Exclusion criteria: Intubated patients on parenteral treatment Allergy to Gum Arabic The study will be conducted in COVID Isolation Centres and Soba University Hospital Khartoum State Sudan. INTERVENTION AND COMPARATOR: Experimental: Intervention Group This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose once daily for four weeks Placebo Comparator: Control group: This group will be provided with pectin powder provided as one-gram-dose once daily for four weeks Both GA and placebo will be in addition to standard care treatment based on local clinical guidelines. MAIN OUTCOMES: Mean change from baseline score of Immune Response to end of the trial. Changes of the level of Tumor Necrosis Factor (TNFα), interleukin IL8, IL6, and IL10 from the baseline values (Four weeks from the start of randomization). Mortality rate: The percentage of deaths among COVID 19 patients received Gum Arabic compared to placebo (Four weeks from the start of randomization]). RANDOMISATION: Randomization (1:1 allocation ratio) and will be conducted using a sequence of computer-generated random numbers by an independent individual. Each participating centre will be assigned a special code generated by the computer. The randomization will be kept by the PI and a research assistant. BLINDING (MASKING): Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) NUMBERS TO BE RANDOMISED (SAMPLE SIZE): 110 eligible patients will be randomly assigned to either GA (n=55) or placebo (n=55) groups. TRIAL STATUS: Protocol Version no 2, 30th June 2020. Recruitment will start on 15th September 2020. The intended completion date is 15th January 2021. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04381871 . Date of trial registration: 11 May 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kaddam L, Babiker R, Ali S, et al. Potential Role of Acacia Senegal (Gum Arabic) as Immunomodulatory Agent among newly diagnosed COVID 19 Patients: A structured summary of a protocol for a randomised, controlled, clinical trial. Trials. 2020. PMID: 32891160. doi:10.1186/s13063-020-04707-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。